Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark F Lew

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
The International Journal of Neuroscience|November 1, 2011
The evidence for disease modification in Parkinson's diseaseMark F Lew
The Clinical Journal of Pain|February 7, 2003
Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reductionMark F Lew
Expert Review of Neurotherapeutics|November 9, 2005
Selegiline orally disintegrating tablets for the treatment of Parkinson's diseaseMark F Lew
The International Journal of Neuroscience|June 18, 2013
Rasagiline treatment effects on parkinsonian tremorMark F Lew
Current Treatment Options in Neurology|March 12, 2003
Gait and Balance Dysfunction in AdultsSalil Manek, Mark F. Lew
Clinical Neuropharmacology|October 3, 2007
Results from a 2-year centralized tolcapone liver enzyme monitoring programMark F Lew, Greg Kricorian
Handbook of Clinical Neurology|April 19, 2011
Polycythemia and choreaMichael M Marvi, Mark F Lew
Toxicon : Official Journal of the International Society on Toxinology|March 17, 2023
BoNT clinical trial update: SialorrheaEmily T Tamadonfar, Mark F Lew
The International Journal of Neuroscience|April 9, 2010
RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studiesMark F Lew, Robert Chinnapongse, Yuxin Zhang, et al.
The International Journal of Neuroscience|August 17, 2011
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing offMark F Lew, Monique Somogyi, Kevin McCague, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
The International Journal of Neuroscience|November 1, 2011
The evidence for disease modification in Parkinson's diseaseMark F Lew
The Clinical Journal of Pain|February 7, 2003
Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reductionMark F Lew
Expert Review of Neurotherapeutics|November 9, 2005
Selegiline orally disintegrating tablets for the treatment of Parkinson's diseaseMark F Lew
The International Journal of Neuroscience|June 18, 2013
Rasagiline treatment effects on parkinsonian tremorMark F Lew
Current Treatment Options in Neurology|March 12, 2003
Gait and Balance Dysfunction in AdultsSalil Manek, Mark F. Lew
Clinical Neuropharmacology|October 3, 2007
Results from a 2-year centralized tolcapone liver enzyme monitoring programMark F Lew, Greg Kricorian
Handbook of Clinical Neurology|April 19, 2011
Polycythemia and choreaMichael M Marvi, Mark F Lew
Toxicon : Official Journal of the International Society on Toxinology|March 17, 2023
BoNT clinical trial update: SialorrheaEmily T Tamadonfar, Mark F Lew
The International Journal of Neuroscience|April 9, 2010
RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studiesMark F Lew, Robert Chinnapongse, Yuxin Zhang, et al.
The International Journal of Neuroscience|August 17, 2011
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing offMark F Lew, Monique Somogyi, Kevin McCague, et al.
Pageof 5